Pandemic Control: Resistant Organisms and Emerging Threats

Pharma Business Daily
Claim your FREE trial subscription!

Pharmaceutical:

Pandemic Control: Resistant Organisms and Emerging Threats

Business Communications Company Inc.
Market Study October 2004

http://www.pharmsinfo.com/bulletin_graphics/bcc_maroon.jpg

The market for new antibiotics and HIV/AIDS treatments was $6.2 billion in 2003 and is rising at an average annual growth rate of 9.1%. It is expected to reach $10.1 billion in 2008. The report provides: A focus on products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS Clarification of the HIV/AIDS pandemic and ongoing efforts to control it Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases Sales for 2003 of new antibiotics and HIV/AIDS drugs, with forecasts through 2008 Trends based on projected sales through 2008 for new products, including supporting analyses for projections.

INTRODUCTION The continuing emergence of drug resistance threatens to reverse progress made during the latter half of the 20th century to effectively treat bacterial and other infectious diseases. In 2004, the problem of antimicrobial resistance poses a global threat to the effective treatment of many bacterial diseases. Furthermore, HIV shares with drug-resistant bacteria the capacity for considerable evolutionary potential. These two organisms not only have jolted the healthcare community out of its relative complacency about the threat of infectious diseases, but have done more to enhance widespread understanding of the importance of population and evolutionary biology to human health and medicine than any other example in the past century. This report provides an explanation of the process of resistance and the technologies involved in approaching this challenging and ominous threat. The study focuses on recently introduced and in-development antibiotics that specifically address the problem of resistance, and HIV/AIDS products, some of which also are targeted at overcoming resistance. The mechanisms by which these drugs function to outwit resistant microbes are described as well, as the likelihood that resistance will develop and within what timeframe. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effect on the market are assessed. Forecasts are provided for the antibiotics and HIV/AIDS drug markets. SCOPE OF STUDY The report provides: A focuses on products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS Clarification of the HIV/AIDS pandemic and ongoing efforts to control it Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases Sales for 2003 of new antibiotics and HIV/AIDS drugs, with forecasts through 2008 Trends based on projected sales through 2008 for new products, including supporting analyses for projections. METHODOLOGY Information to prepare this study was derived from information supplied by product managers, marketing strategists, research executives and others at leading companies involved in the development of new antibiotic and HIV/AIDS products. Data was accessed from government agencies (in particular the World Health Organization, United Nations and Centers for Disease Control and Prevention) and regulatory bodies that monitor and/or regulate pharmaceutical products. Searches of secondary material such as company annual reports and 10Ks, journal articles, prospectus assessments and data from healthcare institutions were also conducted. INFORMATION SOURCES Information to prepare this report was obtained from companies, organizations and institutions involved in the development of antibiotic and HIV/AIDS products and vaccines; industry analysts; healthcare personnel; National Institute of Allergy and Infectious Diseases; the Centers for Disease Control and Prevention and other government agencies; literature searches; annual reports; 10Ks; and product literature. ANALYSTS CREDENTIALS Lynn Gray has been a research analyst in biotechnology and life sciences since 1989 and with BCC since 1996. During that time, she has authored numerous reports in the biomedical field, 20 for BCC alone. BA, University of California, Riverside, 1973.

Number of pages - 252

Number of tables - 62

For full details, please email jenniferc@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.